Skip to content
20-F

Annual Report (Foreign)

ZHONG YUAN BIO-TECHNOLOGY HOLDINGS LIMITED

0001079973-24-001482

← back to feed
Filed
Nov 7, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2024 · Mar 31, 2024 17.99M sh
Shares Diluted FY 2024 · Mar 31, 2023 17.67M sh
Shares Diluted FY 2024 · Mar 31, 2021 17.15M sh
Shares Outstanding FY 2024 · Mar 31, 2024 17.71M sh
Operating Cash Flow FY 2024 · Mar 31, 2024 −$745.82K
Operating Cash Flow restated FY 2024 · Mar 31, 2023 −$1.03M
Long Term Debt FY 2024 · Mar 31, 2024 $1.89M
Short Term Debt FY 2024 · Mar 31, 2024 $1.56M
Short Term Debt FY 2024 · Mar 31, 2023 $1.36M
Cash And Equivalents FY 2024 · Mar 31, 2024 $145.26K
Cash And Equivalents FY 2024 · Mar 31, 2023 $277.84K
Stockholders Equity FY 2024 · Mar 31, 2024 −$204.55K
Stockholders Equity restated FY 2024 · Mar 31, 2023 −$698.88K
Current Liabilities FY 2024 · Mar 31, 2024 $2.48M
Current Liabilities restated FY 2024 · Mar 31, 2023 $2.21M
Total Liabilities FY 2024 · Mar 31, 2024 $3.39M
Total Liabilities restated FY 2024 · Mar 31, 2023 $2.82M
Current Assets FY 2024 · Mar 31, 2024 $2.03M
Current Assets restated FY 2024 · Mar 31, 2023 $1.04M
Total Assets FY 2024 · Mar 31, 2024 $3.17M
Total Assets restated FY 2024 · Mar 31, 2023 $2.13M
Eps Diluted FY 2024 · Mar 31, 2024 −$0.02
Eps Diluted FY 2024 · Mar 31, 2023 $0.12
Eps Diluted FY 2024 · Mar 31, 2021 $0.16
Eps Basic FY 2024 · Mar 31, 2024 −$0.02
Eps Basic FY 2024 · Mar 31, 2023 $0.12
Eps Basic FY 2024 · Mar 31, 2021 $0.16
Sga Expense FY 2024 · Mar 31, 2024 $897.52K
Sga Expense restated FY 2024 · Mar 31, 2023 $917.77K
Rd Expense FY 2024 · Mar 31, 2024 $493.84K
Rd Expense restated FY 2024 · Mar 31, 2023 $526.76K
Net Income FY 2024 · Mar 31, 2024 $271.87K
Net Income restated FY 2024 · Mar 31, 2023 −$2.2M
Operating Income FY 2024 · Mar 31, 2024 $266.56K
Operating Income restated FY 2024 · Mar 31, 2023 −$1.61M
Cost Of Revenue FY 2024 · Mar 31, 2024 $206.37K
Cost Of Revenue FY 2024 · Mar 31, 2023 $144.68K
Capex FY 2024 · Mar 31, 2023 $22.37K
Revenue FY 2024 · Mar 31, 2022 $2.33M